MedTrace Logo

Outcomes of Autologous Bone Marrow Mononuclear Cell Administration in the Treatment of Neurologic Sequelea in Children With Spina Bifida

NCT05472428 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2022-07-25

No results posted yet for this study

Summary

The aim of this study was to evaluate the safety and efficacy of autologous bone marrow mononuclear cell infusion in the management of neurological sequelae in children with spina bifida

Conditions

  • Stem Cell Infusion

Interventions

COMBINATION_PRODUCT

Autologous bone marrow mononuclear cell transplantation

Transplantation of Autologous Bone Marrow Mononuclear cells

Sponsors & Collaborators

  • Vinmec Health Care System (Vingroup Joint Stock Company)

    collaborator UNKNOWN

  • Vinmec Research Institute of Stem Cell and Gene Technology

    lead OTHER

Principal Investigators

  • Liem T Nguyen, MD., PhD · Vinmec Research Institute of Stem Cell and Gene Technology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-01
Primary Completion
2020-12-25
Completion
2021-08-31

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05472428 on ClinicalTrials.gov